College of Food Science and Technology, Ocean University China, Qingdao, China.
National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases, National Institute for Communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.
Commun Biol. 2024 Sep 18;7(1):1172. doi: 10.1038/s42003-024-06850-x.
Clostridioides difficile infection (CDI) is a common healthcare-associated infection and the leading cause of gastroenteritis-related deaths worldwide. To investigate the effects of peptide composition of different protein products on CDI, we analyzed and compared the peptide sequences and compositions from Engraulis japonicus and Glycine max using Ultra High Performance Liquid Chromatography Tandem Mass Spectrometry (UPLC-MS/MS). An animal model of CDI was also established to investigate the potential therapeutic effects of these peptides in vivo. The peptide compositions of E. japonicus and G. max differed, with only 11% of the peptide sequences being identical. Oral administration of the tested peptides could reduce intestinal inflammation, repair the intestinal barrier, increase the proportion of beneficial bacteria, and reduce the proportion of harmful bacteria, providing a therapeutic effect against CDI. However, the peptides may differ considerably in some aspects. E. japonicus peptides were superior to G. max peptides in promoting colon epithelial cell proliferation and repairing tight intestinal cell junctions. Interestingly, the two sources of peptides have different effects on the cecal microbiome. E. japonicus peptides can effectively restore the diversity and richness of intestinal microbiota, while G. max peptides have poor regulatory effects on the intestinal microbiota structure. Overall, E. japonicus peptides showed better results than G. max peptides in treating CDI. This study supports the potential treatment of CDI with natural peptides and promotes the development of specialty foods for CDI enteritis. Clostridioides difficile infection (CDI) is a common healthcare-associated infection and the leading cause of gastroenteritis-related deaths worldwide. To investigate the effects of peptide composition of different protein products on CDI, we analyzed and compared the peptide sequences and compositions from Engraulis japonicus and Glycine max using Ultra High Performance Liquid Chromatography Tandem Mass Spectrometry (UPLC-MS/MS). An animal model of CDI was also established to investigate the potential therapeutic effects of these peptides in vivo. The peptide compositions of E. japonicus and G. max differed, with only 11% of the peptide sequences being identical. Oral administration of the tested peptides could reduce intestinal inflammation, repair the intestinal barrier, increase the proportion of beneficial bacteria, and reduce the proportion of harmful bacteria, providing a therapeutic effect against CDI. However, the peptides may differ considerably in some aspects. E. japonicus peptides were superior to G. max peptides in promoting colon epithelial cell proliferation and repairing tight intestinal cell junctions. Interestingly, the two sources of peptides have different effects on the cecal microbiome. E. japonicus peptides can effectively restore the diversity and richness of intestinal microbiota, while G. max peptides have poor regulatory effects on the intestinal microbiota structure.
艰难梭菌感染（CDI）是一种常见的与医疗保健相关的感染，也是全球范围内导致与胃肠炎相关的死亡的主要原因。为了研究不同蛋白质产品的肽组成对 CDI 的影响，我们使用超高效液相色谱串联质谱法（UPLC-MS/MS）分析和比较了日本鳀鱼和大豆的肽序列和组成。还建立了 CDI 的动物模型，以研究这些肽在体内的潜在治疗效果。测试肽的口服给药可以减少肠道炎症，修复肠道屏障，增加有益细菌的比例，并减少有害细菌的比例，从而对 CDI 提供治疗效果。然而，肽在某些方面可能有很大的不同。日本鳀鱼和大豆的肽组成不同，只有 11％的肽序列相同。口服给予测试肽可减少肠道炎症，修复肠道屏障，增加有益细菌的比例，减少有害细菌的比例，对 CDI 有治疗作用。然而，肽在某些方面可能有很大的不同。日本鳀鱼肽在促进结肠上皮细胞增殖和修复紧密的肠细胞连接方面优于大豆肽。有趣的是，两种来源的肽对盲肠微生物组有不同的影响。日本鳀鱼肽可以有效恢复肠道微生物群的多样性和丰富度，而大豆肽对肠道微生物群结构的调节作用较差。总的来说，日本鳀鱼肽在治疗 CDI 方面比大豆肽表现出更好的效果。这项研究支持用天然肽治疗 CDI，并促进治疗 CDI 肠炎的特殊食品的发展。
